Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Dianthus Therapeutics (DNTH) Stock Price & Analysis

445 Followers

DNTH Stock Chart & Stats

$83.01-$2.80(-3.26%)
At close: 4:00 PM EST
$75$100Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$80.34 - $85.87
52-Week Range
$33.85 - $117.88
Previous Close
$85.81
Volume
N/A
Average Volume (3M)
946.80K
Market Cap
$4.80B
Enterprise Value
$4.21B
Total Cash (Recent Filing)
$837.78M
Total Debt (Recent Filing)
$1.21M
Price to Earnings (P/E)
2767.0
Beta
0.85
Next Earnings
Mar 16, 2027 (Est.)
EPS Estimate
-0.96
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Capital Base

Extremely low leverage limits financial risk from borrowing and preserves flexibility for research, development, and other capital needs. The substantially larger equity base provides Dianthus with a stronger solvency position than many development-stage companies, although it does not yet generate profits.

Focused Complement-system Platform

A focused therapeutic strategy around Complement Factor C1s gives Dianthus a clear scientific identity and concentrates resources on a defined mechanism. Targeting severe autoimmune and inflammatory diseases could support meaningful clinical value if development succeeds, creating a platform for future indications.

Improved Net Loss Versus 2025

The substantial reduction in net loss indicates that reported earnings performance improved materially from the prior annual period. If sustained, lower losses could extend the company’s financial runway and reduce the pace at which its substantial capital base is consumed during ongoing clinical development.

Bears Say

No Commercial Product Revenue

Without marketed products, Dianthus lacks a recurring commercial revenue stream to fund operations and validate its business model through customer demand. Financial progress therefore remains dependent on development outcomes and external financing until a therapy can be successfully approved and commercialized.

Significant Cash Burn

Heavy negative operating and free cash flow shows that clinical development is consuming substantial capital rather than generating cash internally. If this burn rate persists, Dianthus will require continued access to financing or other funding sources, potentially diluting shareholders or limiting development flexibility.

Loss-making And Volatile Revenue

Small, volatile revenue is insufficient to offset the high research and operating costs typical of Dianthus’s development-stage model. Deeply negative margins and continuing operating losses leave results dependent on clinical progress and financing rather than a stable earnings base, increasing business-model uncertainty.

Dianthus Therapeutics News

DNTH FAQ

What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $33.85 and its highest was $117.88 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $4.80B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s next earnings report is estimated for Mar 16, 2027 (not yet confirmed), which is in 130 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Nov 04, 2026. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.945 by $0.135.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.96.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 55,934,380 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.945. Following the earnings report the stock price went down -3.263%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Hedge funds hold Dianthus Therapeutics shares: the largest hedge-fund position in Dianthus Therapeutics is 71,884,651 shares, and hedge funds decreased their holdings by 2.4M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology